#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized recommendations for anticoagulant therapy during the postoperative period. One option to bridge the time until therapeutic INR is achieved after LVAD implantation is the low molecular weight heparin (LMWH) enoxaparin, which was investigated for its efficacy and safety in this indication by experts from Kansas, USA, cited in the following study.
Source: Thromboprophylaxis 28. 11. 2023

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.
Source: Thromboprophylaxis 28. 11. 2023

News Picking from the Red Book of the CHS: What's New in This Year's Recommendations for Diagnosis and Treatment of AML?

In recent years, there have been significant advances in the diagnosis and therapy of acute myeloid leukemia (AML). High-quality laboratory diagnostics (molecular genetics, cytogenetics, and flow cytometry) are absolutely essential, and monitoring measurable residual disease is becoming increasingly important. The range of treatment options is also beginning to expand. The content of the latest 'Recommendations for the Diagnosis and Treatment of Acute Myeloid Leukemia (AML),' which are part of this year's updated 'Red Book' of the Czech Hematology Society ČLS JEP (CHS), is primarily based on the 2022 European Leukemia Network (ELN) guidelines and offers, among other things, an updated disease classification and risk stratification, as well as an overview of current treatment options for both intensive and non-intensive regimens.
Source: Acute Myeloid Leukemia 29. 11. 2023

News Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins –⁠ A Systematic Review of the Literature

The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in patients with primary immunodeficiency (PID) who had not previously been treated with this modality. There was insufficient data available for such a defined population because SCIGs had typically been introduced into studies only after intravenously administered immunoglobulins (IVIG).
Source: Primary and Secondary Immunodeficiencies 1. 12. 2023

News 10 Warning Signs of Primary and Secondary Immunodeficiencies

The Jeffrey Modell Foundation (JMF) proposed 10 warning signs of primary immunodeficiencies (PID). The study presented below examined whether they are applicable to secondary immunodeficiencies (SID) and whether there are any additional signs that could help in diagnosing SID.
Source: Primary and Secondary Immunodeficiencies 1. 12. 2023

News Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses

Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with dupilumab manage to reach centers where the treatment is provided. It's even more unfortunate when there's ample evidence that the effects of this therapy on disease manifestations and overall quality of life extend beyond just the patients. It also impacts the lives of their close ones who care for those with atopic dermatitis. Head of the Clinic of Venereal and Skin Diseases at Charles University and the University Hospital Hradec Králové Doc. MUDr. Miloslav Salavec, CSc., evaluates how dupilumab has performed over several years of real clinical practice and the specific benefits it has brought to patients.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 12. 2023

News How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?

What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the patients' perspective, what do they fear, what approaches do they prefer, and why? Lozano et al. included a discussion on this topic in their review article for Expert Review of Hematology, which can be helpful in clinical practice for better understanding patients' needs and adjusting treatment algorithms.
Source: Immune Thrombocytopenia 21. 11. 2023

News Romiplostim brings benefit also to patients with ITP lasting less than 1 year

What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?
Source: Immune Thrombocytopenia 21. 11. 2023

News Stabilization of Transthyretin and Long-term Survival of Patients with Cardiac Amyloidosis

Tafamidis is used in the therapy of transthyretin amyloid cardiomyopathy (ATTR-CM), which has proven its benefit in the ATTR-ACT clinical study. The results of its open-label extension study show that early diagnosis and prompt initiation of therapy are crucial.
Source: Amyloidosis 20. 11. 2023

News Reduction of Inflammation in Vertebral Bodies and Posterolateral Structures of the Spine in Patients with Ankylosing Spondylitis Treated with Tofacitinib

A post hoc analysis of a phase II study with tofacitinib in patients with active ankylosing spondylitis (AS) evaluated the suppression of spinal inflammation using magnetic resonance imaging (MRI) based on the Canadian-Danish scoring system (CANDEN), which allows for the assessment of changes in posterolateral structures of the spine, characteristic of AS involvement.
Source: Arthritis 23. 11. 2023

News Reduction of Enthesitis in Patients with Psoriatic Arthritis Taking Tofacitinib

Inflammation in the area where a tendon, ligament, or joint capsule attaches to the bone occurs in 35–50% of patients with psoriatic arthritis (PsA). Its presence is associated with higher activity of PsA, and its intensity correlates with the degree of joint damage. Patients with enthesitis are generally in worse functional status and report greater fatigue, pain, and decreased productivity. How can treatment with tofacitinib affect this important domain of PsA?
Source: Arthritis 24. 11. 2023

News How do body weight and metabolic parameters change in patients first hospitalized for psychosis?

The most common cause of death in patients with schizophrenia is cardiovascular disease, which is closely related to obesity or metabolic syndrome. The study presented below examined changes in body weight and metabolic parameters during the first hospitalization of these patients.
Source: Modern Treatment of Schizophrenia 24. 11. 2023

News FEIBA in Real Clinical Practice –⁠ Fresh Data from the Observational Study FEIBA GO

FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.
Source: Hemophilia 27. 11. 2023

News Untreated Bleeding in Hemophilia A –⁠ An Underestimated Problem? To What Extent?

How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.
Source: Hemophilia 27. 11. 2023

News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year −⁠ A US Experience

The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
Source: Hemophilia 27. 11. 2023

1 39 40 41 42 43 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#